Jun 11, 2026 07:00AM
Jun 11, 2026 07:00AM
Jun 24, 2024 03:00AM
Jun 17, 2024 06:45AM
May 31, 2024 09:57AM
Feb 26, 2024 11:30PM
Dec 21, 2023 04:00PM Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Oct 3, 2023 04:50PM
Oct 2, 2023 04:35PM
Oct 2, 2023 04:30PM
Sep 25, 2023 08:44AM
Jan 11, 2023 08:36AM
Dec 19, 2022 02:30PM
Dec 8, 2022 06:45AM Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
Nov 22, 2022 03:57PM
Nov 22, 2022 03:57PM
Nov 11, 2022 02:00AM
Oct 14, 2022 07:30AM
Aug 22, 2022 09:57AM
Jun 9, 2022 04:30AM
Apr 22, 2022 08:00AM Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
Dec 8, 2021 07:00AM
Dec 2, 2021 09:49AM
Nov 23, 2021 05:26PM
Nov 23, 2021 05:24PM
Oct 7, 2021 06:15PM
Sep 15, 2021 04:41PM
Sep 15, 2021 04:40PM Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

67,115 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All